Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Osama Alalao

Urology Stuart, FL Medical Doctor

NPI 1619464781 CMS profile 4447180

3801 S Kanner Hwy, Stuart, FL 34994

Open in the dashboard

General payments

$9,886

67 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Osama Alalao of Stuart, FL is reported in the CMS Open Payments database as having received $9,886 across 67 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $175 1
2024 General $938 10
2023 General $217 2
2022 General $266 5
2021 General $1,285 7
2020 General $1,888 16
2019 General $5,117 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Osama Alalao
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Osama Alalao were reported at $175. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Osama Alalao Urology median Middle half National median
2019 $5,117 $480 $147–$1,201 $163
2020 $1,888 $246 $87–$645 $114
2021 $1,285 $358 $111–$1,000 $132
2022 $266 $476 $143–$1,263 $149
2023 $217 $560 $168–$1,461 $160
2024 $938 $563 $170–$1,464 $164
2025 $175 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $4,850 26 payments
  2. Olympus Corporation of the Americas $1,649 17 payments
  3. KARL STORZ Endoscopy-America $1,046 5 payments
  4. Verathon Inc. $800 1 payment
  5. Teleflex LLC $625 6 payments
  6. C. R. Bard, Inc. & Subsidiaries $180 2 payments
  7. Astellas Pharma US Inc $164 2 payments
  8. Davol Inc. $146 1 payment
  9. PROCEPT BioRobotics Corporation $124 1 payment
  10. Laborie Medical Technologies Corp. $120 1 payment
  11. Other $182 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $5,159 22 payments
  2. Food and Beverage $3,587 41 payments
  3. Consulting Fee $800 1 payment
  4. Honoraria $175 1 payment
  5. Education $164 2 payments
Products named General payments · program years 2019–2025
  1. General BPH $2,211 8 payments
  2. GENERAL KIDNEY STONE DISEASE $1,312 4 payments
  3. PK SuperPulse $1,033 7 payments
  4. ShockPulse - SE $1,033 7 payments
  5. NEPHROSCOPE MIP M $888 1 payment
  6. NPD Clinical Study $800 1 payment
  7. Olympus Cystoscopes $616 10 payments
  8. Olympus Laser Devices $616 10 payments
  9. Olympus Resection Disposables $616 10 payments
  10. General - Kidney Stone Disease $539 5 payments
  11. Other $2,407 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,534

Median for Urology: 1,053

Drug cost

$146,982

Median for Urology: $101,464

Branded share of claims

28.4%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 101 $81,382
Gemtesa Vibegron Brand 36 $29,751
Tamsulosin Hcl Generic 506 $7,864
Potassium Citrate Er Potassium Citrate Brand 62 $5,568
Premarin Estrogens, Conjugated Brand 11 $4,842
Finasteride Generic 245 $3,665
Trospium Chloride Generic 49 $2,827
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 40 $2,056
Oxybutynin Chloride Er Oxybutynin Chloride Brand 84 $1,478
Oxybutynin Chloride Generic 59 $1,066

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$140,264

Of which drugs: $8,250

Medicare patients

516

Average age 76

Services billed

3,047

128 women, 388 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 43%
Cancer 35%
Chronic kidney disease 32%
Diabetes 31%
Atrial fibrillation 25%
Depression 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 14 27 $52

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

67 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record